Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: RRT020
MIFTS: 41

Rare Tumor

Categories: Cancer diseases, Eye diseases, Rare diseases
Genes Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Rare Tumor

About this section

MalaCards integrated aliases for Rare Tumor:

Name: Rare Tumor 58
Rare Neoplasm 58

Classifications:

MalaCards categories:
Global: Rare diseases Cancer diseases
Anatomical: Eye diseases
See all MalaCards categories (disease lists)


External Ids:

UMLS via Orphanet 72 C0375111
Orphanet 58 ORPHA98057
Sources

Summaries for Rare Tumor

About this section
MalaCards based summary : Rare Tumor, also known as rare neoplasm, is related to desmoplastic small round cell tumor and paraganglioma. An important gene associated with Rare Tumor is EWSR1 (EWS RNA Binding Protein 1), and among its related pathways/superpathways are Cytokine Signaling in Immune system and Cytoskeletal Signaling. The drugs leucovorin and Pemetrexed have been mentioned in the context of this disorder. Affiliated tissues include breast, pancreas and liver, and related phenotypes are homeostasis/metabolism and mortality/aging

Sources

Related Diseases for Rare Tumor

About this section

Diseases in the Rare Tumor family:

Rare Eye Tumor

Diseases related to Rare Tumor via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 684)
# Related Disease Score Top Affiliating Genes
1 desmoplastic small round cell tumor 32.3 EWSR1 DES
2 paraganglioma 31.8 SST RET KIT
3 spindle cell sarcoma 30.4 NF2 DES ACTC1
4 fibromatosis 30.2 DES ACTC1
5 leiomyosarcoma 30.2 KIT DES ACTC1
6 hemangioma 30.2 RET KIT ACTC1
7 lipomatosis, multiple 30.1 KIT EWSR1 DES
8 leiomyoma 30.1 KIT DES ACTC1
9 sarcoma, synovial 30.0 KIT EWSR1 DES
10 rhabdoid tumor predisposition syndrome 1 29.9 DES ACTC1
11 teratoma 29.9 SST KIT ACTC1
12 syringocystadenoma papilliferum 29.9 DES ACTC1
13 carcinosarcoma 29.9 KIT DES ACTC1
14 spindle cell lipoma 29.9 DES ACTC1
15 pulmonary blastoma 29.8 SST DES ACTC1
16 angiomyolipoma 29.7 KIT DES ACTC1
17 chondroma 29.7 KIT ACTC1
18 rhabdomyosarcoma 29.7 KIT EWSR1 DES ACTC1
19 congenital fibrosarcoma 29.7 EWSR1 DES ACTC1
20 parachordoma 29.7 DES ACTC1
21 desmoid tumor 29.7 KIT DES ACTC1
22 glomangioma 29.7 DES ACTC1
23 angiolipoma 29.6 DES ACTC1
24 alveolar soft part sarcoma 29.6 RET EWSR1 DES ACTC1
25 ossifying fibromyxoid tumor 29.6 DES ACTC1
26 hemangiopericytoma, malignant 29.6 KIT DES ACTC1
27 neurofibroma 29.6 NF2 KIT ACTC1
28 neurilemmoma 29.6 NF2 KIT DES ACTC1
29 follicular dendritic cell sarcoma 29.6 KIT FCER2 CR2
30 chondromyxoid fibroma 29.5 DES ACTC1
31 fibrous histiocytoma 29.5 KIT EWSR1 DES ACTC1
32 myoepithelial carcinoma 29.5 EWSR1 ACTC1
33 dermatofibrosarcoma protuberans 29.5 KIT DES ACTC1
34 malignant fibrous histiocytoma 29.5 KIT EWSR1 DES ACTC1
35 ewing sarcoma 29.5 RET KIT EWSR1 DES
36 embryonal rhabdomyosarcoma 29.4 EWSR1 DES ACTC1
37 perivascular epithelioid cell tumor 29.4 KIT DES ACTC1
38 adenosarcoma 29.4 KIT DES ACTC1
39 embryonal sarcoma 29.4 KIT DES
40 reticulum cell sarcoma 29.3 FCER2 DES CR2 ACTC1
41 neuroma 29.3 RET NF2 KIT
42 meningioma, familial 29.3 SST RET NF2 LATS2
43 sarcoma 29.2 RET NF2 KIT EWSR1 DES ACTC1
44 myxofibrosarcoma 29.2 KIT EWSR1 DES
45 perineurioma 29.2 KIT ACTC1
46 muscle cancer 29.2 KIT EWSR1 DES
47 inflammatory myofibroblastic tumor 29.2 KIT EWSR1 DES CR2 ACTC1
48 constipation 29.2 SST RET KIT EWSR1
49 pleomorphic liposarcoma 29.1 KIT EWSR1 DES ACTC1
50 malignant peripheral nerve sheath tumor 29.1 NF2 KIT ACTC1

Graphical network of the top 20 diseases related to Rare Tumor:



Diseases related to Rare Tumor
Sources

Symptoms & Phenotypes for Rare Tumor

About this section

MGI Mouse Phenotypes related to Rare Tumor:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 9.85 ACTC1 CR2 DES FCER2 KIT LATS2
2 mortality/aging MP:0010768 9.7 ACTC1 CR2 DES FCER2 FSCN1 KIT
3 muscle MP:0005369 9.1 ACTC1 DES KIT LATS2 MMP2 RET
Sources

Drugs & Therapeutics for Rare Tumor

About this section

Drugs for Rare Tumor (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 116)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
leucovorin Approved Phase 2, Phase 3 58-05-9 6006 143
2
Pemetrexed Approved, Investigational Phase 2, Phase 3 137281-23-3, 150399-23-8 60843 446556
3
Methylcobalamin Approved, Investigational Phase 2, Phase 3 13422-55-4
4
Hydroxocobalamin Approved Phase 2, Phase 3 13422-51-0 15589840 11953898
5
Bevacizumab Approved, Investigational Phase 2, Phase 3 216974-75-3
6
Folic acid Approved, Nutraceutical, Vet_approved Phase 2, Phase 3 59-30-3 6037
7
Cyanocobalamin Approved, Nutraceutical Phase 2, Phase 3 68-19-9 44176380
8
Cobalamin Experimental Phase 2, Phase 3 13408-78-1 6857388
9 Vitamins Phase 2, Phase 3
10 Vitamin B Complex Phase 2, Phase 3
11 Folic Acid Antagonists Phase 2, Phase 3
12 Folate Phase 2, Phase 3
13 Vitamin B9 Phase 2, Phase 3
14 Vitamin B 12 Phase 2, Phase 3
15 Vitamin B12 Phase 2, Phase 3
16
Vincristine Approved, Investigational Phase 2 57-22-7, 2068-78-2 5978
17
Doxorubicin Approved, Investigational Phase 2 23214-92-8 31703
18
Mitotane Approved Phase 2 53-19-0 4211
19
Etoposide Approved Phase 2 33419-42-0 36462
20
Everolimus Approved Phase 2 159351-69-6 70789204 6442177
21
Trastuzumab Approved, Investigational Phase 2 180288-69-1 9903
22
afatinib Approved Phase 2 439081-18-2, 850140-72-6 10184653
23
Dabrafenib Approved, Investigational Phase 2 1195765-45-7 44462760 44516822
24
Gefitinib Approved, Investigational Phase 2 184475-35-2 123631
25
Rucaparib Approved, Investigational Phase 2 283173-50-2 9931954
26
Progesterone Approved, Vet_approved Phase 2 57-83-0 5994
27
Tamoxifen Approved Phase 2 10540-29-1 2733526
28
rituximab Approved Phase 2 174722-31-7 10201696
29
Olaparib Approved Phase 2 763113-22-0 23725625
30
Vemurafenib Approved Phase 2 918504-65-1 23252090 42611257
31
Palbociclib Approved, Investigational Phase 2 571190-30-2 5005498 11431660 5330286
32
Durvalumab Approved, Investigational Phase 2 1428935-60-7
33
Crizotinib Approved Phase 2 877399-52-5 11626560 10366136 10366137 10366138 10366139 10366140 10366141
34
Osimertinib Approved Phase 2 1421373-65-0 71496458
35
Atezolizumab Approved, Investigational Phase 2 1380723-44-3
36
Cisplatin Approved Phase 2 15663-27-1 2767 441203 84093
37
Paclitaxel Approved, Vet_approved Phase 2 33069-62-4 36314
38
Ifosfamide Approved Phase 2 3778-73-2 3690
39
Gemcitabine Approved Phase 2 95058-81-4 60750
40
Oxaliplatin Approved, Investigational Phase 2 61825-94-3 43805 6857599 5310940 9887054
41
Levodopa Approved Phase 2 59-92-7 6047
42
Salmon calcitonin Approved, Investigational Phase 2 47931-85-1 16129616
43
Dopamine Approved Phase 2 51-61-6, 62-31-7 681
44
Imiquimod Approved, Investigational Phase 1, Phase 2 99011-02-6 57469
45
Tremelimumab Investigational Phase 2 745013-59-6
46
Calcitonin gene-related peptide Investigational Phase 2 83652-28-2
47
Liposomal doxorubicin Phase 2 31703
48 Etoposide phosphate Phase 2
49 polysaccharide-K Phase 2
50
Erlotinib Hydrochloride Phase 2 183319-69-9 176871

Interventional clinical trials:

(show all 45)
# Name Status NCT ID Phase Drugs
1 A Phase II-III Randomized Trial Pemetrexed-Cisplatin Chemotherapy With or Without Bevacizumab (Avastin), 15 mg/kg, for Malignant Pleural Mesothelioma (MPM) Completed NCT00651456 Phase 2, Phase 3 Standard Chemotherapy (Pemetrexed and Cisplatin);Standard Chemotherapy (Pemetrexed and Cisplatin) + Bevacizumab
2 Phase II Trial of Surgical Resection and Heated Intraperitoneal Peritoneal Chemotherapy (HIPEC) for Adrenocortical Carcinoma Completed NCT01833832 Phase 2 Cisplatin;sodium thiosulfate
3 A Study of Combination Chemotherapy & Surgical Resection in the Tx of Adrenocortical Cancer: Mitotane & Continuous Infusion Doxorubicin, Vincristine & Etoposide w/the P-glycoprotein Antagonist, Tariquidar (XR9576), Before & After Surgical Resection Completed NCT00071058 Phase 2 XR9576 (Tariquidar)
4 Efficacy and Safety of Targeted Precision Therapy in Refractory Tumor With Druggable Molecular Event Recruiting NCT03239015 Phase 2 Gefitinib;Erlotinib;Afatinib;Trastuzumab;Oxazolidine;Olaparib;Everolimus;Cabozantinib;Vemurafenib;Dabrafenib;Palbociclib
5 A Phase 2 Multicenter, Open-label Study of Rucaparib as Treatment for Solid Tumors Associated With Deleterious Mutations in Homologous Recombination Repair Genes Recruiting NCT04171700 Phase 2 Rucaparib
6 Phase II Trial of Surgical Resection and Heated Intraperitoneal Peritoneal Chemotherapy (HIPEC) for Adrenocortical Carcinoma Recruiting NCT03127774 Phase 2 Cisplatin;Sodium thiosulfate
7 A Phase II Study of Durvalumab (MEDI4736) (Anti-PD-L1 Antibody) in Combination With Tremelimumab (Anti-CTLA-4 Antibody) in Subjects With Advanced Rare Solid Tumors Recruiting NCT02938793 Phase 2 Durvalumab;Tremelimumab
8 Phase II Study of Hormone Therapy With Tamoxifen in Patients With Well Differentiated Neuroendocrine Tumors and Hormone Receptor Positive Expression Recruiting NCT03870399 Phase 2 Tamoxifen
9 Bendamustine and Rituximab for the Treatment of Splenic Marginal Zone Lymphoma. The International Extranodal Lymphoma Study Group (IELSG) 36 Phase II Prospective Study Active, not recruiting NCT02853370 Phase 2 Bendamustine and Rituximab
10 Platform Study of Genotyping Guided Precision Medicine for Rare Tumors in China Not yet recruiting NCT04423185 Phase 2 Osimertinib 80 MG;Dacomitinib 45 MG;Alectinib 150 MG;Crizotinib 250 MG;Pyrotinib 160/80 MG;Imatinib 400 MG;Olaparib 150 MG;Palbociclib 125mg;Vemurafenib 240 MG;Sintilimab 100MG;Atezolizumab 1200 MG;Durvalumab 500 MG
11 A Single-center, Open Label Study for Evaluation of the Safety and Efficacy of Oshadi D and Oshadi R for Malignant Mesothelioma Treatment - A Phase IIa Study Suspended NCT01627795 Phase 1, Phase 2 Oshadi D and Oshadi R
12 Prospective Phase II Study Evaluating a Multimodal Care of Inguinal Node Metastasis in Squamous Cell Carcinoma of the Penis by Bilateral Lymphadenectomy and Chemotherapy TIP Suspended NCT02817958 Phase 2 Chemotherapy TIP
13 Open Labeled Phase II Study Evaluating Efficacy and Safety of Chemotherapy With Gemcitabine - Oxaliplatin Combination for Advanced Refractory Thyroid Cancer Patients Terminated NCT02472080 Phase 2 gemcitabine -oxaliplatine combination
14 Efficacy and Tolerance of RADIOEMBOLIZATION for Patients With Unresectable Intrahepatic Cholangiocarcinoma With Tumor Progression After First-line Therapy Terminated NCT01383746 Phase 1, Phase 2
15 Clinical Evaluation of 18F-DOPA Positron Emission Tomography in Medullary Thyroid Cancer. Terminated NCT00647140 Phase 2
16 Phase I/II Study of Peptide Vaccination Associated With Tumoral Immunomodulation With Proinflammatory Cytokines and Imiquimod in Patients With Advanced Metastatic Melanoma Terminated NCT01191034 Phase 1, Phase 2 Vaccine MAGE-3.A1 peptide, or the NA17.A2 peptide + IL-2, IFN-α and GMCSF, Imiquimod.
17 Phase I/II Study of Peptide Vaccination Associated With GM-CT-01, a Galactomannan Oligomer That Inhibits Galectin-3, in Patients With Advanced Metastatic Melanoma Terminated NCT01723813 Phase 1, Phase 2
18 Phase I/II Study of Xeloda and Gleevec in Patients With Advanced Solid Tumors Completed NCT00183833 Phase 1 capecitabine, imatinib mesylate
19 Imatinib Mesylate And Cyclophosphamide In Metronomic Administration: Dose Escalation Study Of Imatinib Mesylate in Patient With Rare Tumor (Phase I Study) Completed NCT01046487 Phase 1 Imatinib mesylate, Cyclophosphamide (Dosing level 1 );Imatinib mesylate, Cyclophosphamide (Dosing level 2);Imatinib mesylate, Cyclophosphamide (Dosing level 3)
20 A Phase I Dose Escalation Study of Autologous Expanded Natural Killer (NK) Cells for Immunotherapy of Relapsed Refractory Neuroblastoma With Dinutuximab +/- Lenalidomide Recruiting NCT02573896 Phase 1 Ch14.18;Lenalidomide
21 A Phase I/II Trial of IL-13-PE in Patients With Treatment Refractory Malignancies With a Focus on Metastatic and Locally Advanced Adrenocortical Carcinoma Terminated NCT01832974 Phase 1 IL-13-PE
22 Contribution of F18-FDG PET/CT to the Early Assessment of Pazopanib Therapy Efficacy in Advanced Soft Tissue Sarcoma Unknown status NCT01594203
23 Evaluation of New Biomarkers Predictive of Efficacy Betablockers in PEComa and Vascular Pediatric Tumors Completed NCT02334930
24 Survival After Hepatectomy for Combined Hepatocellular Cholagiocarcinoma Completed NCT03178409
25 A Pilot Study of Combined Immunochemotherapy Followed by Reduced Dose RT for Patients With Newly Diagnosed Primary Central Nervous System Lymphoma Completed NCT00594815 Cytarabine, Leucovorin, Methotrexate, Procarbazine, Rituximab, Vincristine
26 Clinicopathological Importance of Colorectal Medullary Carcinoma: Retrospective Cohort Study Completed NCT03774862
27 Procurement of Blood and Tissue From Patients With Primary and Metastatic Alveolar Soft Part Sarcoma and Blood From Healthy Controls for In Vitro and In Vivo Model Development Completed NCT00340353
28 Natural History and Tissue Acquisition Study of Adrenocortical Carcinoma Completed NCT02015026
29 Sentinel Lymph Node Biopsy in Porocarcinoma: A Case Reports Completed NCT03647631
30 Retrospective Study of Cases of Small Cell Lung Cancer (SCLC) That Appeared During Treatment of Another Lung Carcinoma With or Without Oncogenic Activation (TransCPC) Completed NCT03419286
31 International Pediatric Adrenocortical Tumor Registry Recruiting NCT00700414
32 Natural History Study of Children and Adults With Chordoma Recruiting NCT03910465
33 Natural History and Biospecimen Acquisition Study for Children and Adults With Rare Solid Tumors Recruiting NCT03739827
34 Neuroblastoma Biology Studies Recruiting NCT00904241
35 International Pleuropulmonary Blastoma Registry for PPB, DICER1 and Associated Conditions Recruiting NCT03382158
36 Clinico-biological Study/Characterization of Rhabdomyosarcoma in AYA (Adolescents and Young Adults, 15-25-year-old Patients) Recruiting NCT03462888
37 DICER1-Related Pleuropulmonary Blastoma Cancer Predisposition Syndrome: A Natural History Study Recruiting NCT01247597
38 Molecular-guided Therapy for the Treatment of Patients With Relapsed and Refractory Childhood Cancers Active, not recruiting NCT02162732
39 A Feasibility Trial Using Molecular-Guided Therapy for the Treatment of Patients With Relapsed and Refractory Childhood Cancer Active, not recruiting NCT01802567
40 Family Study of Head and Neck Cancers in Taiwan Active, not recruiting NCT00342147
41 Elucidating the Genetic Basis of the Pleuropulmonary Blastoma (PPB) Familial Cancer Syndrome Active, not recruiting NCT00565903
42 Retrospective Study of Optimal Methods of Disease Progression and Survival Analysis in Children and Adults With Adrenocortical Cancer (ACC) Enrolling by invitation NCT04358107
43 Measurement of Circulating Tumor Cells in Prostate Cancer Not yet recruiting NCT04101305
44 Rare Tumor Case Review Terminated NCT00229879
45 Topical Anesthesia to Decrease the Trigeminal-Cardiac Reflex During Intra-arterial Injection of Chemotherapy for Retinoblastoma in Children. Withdrawn NCT02955524 Early Phase 1 Tetracaine 0.5%;Lidocaine hydrochloride ophthalmic gel 3.5%

Search NIH Clinical Center for Rare Tumor

Sources

Genetic Tests for Rare Tumor

About this section
Sources

Anatomical Context for Rare Tumor

About this section

MalaCards organs/tissues related to Rare Tumor:

40
Breast, Pancreas, Liver, Thyroid, Lung, Bone, Kidney
Sources

Publications for Rare Tumor

About this section

Articles related to Rare Tumor:

(show top 50) (show all 10206)
# Title Authors PMID Year
1
Scrotal leiomyoma a rare benign intra-scrotal mass could lead to unnecessary orchiectomy. 61
32368497 2020
2
Successful surgical management of recurrent urachal adenocarcinoma: A case report. 61
32322529 2020
3
Intra-scrotal extra-testicular schwannoma: A case report and literature review. 61
32373470 2020
4
A tale of autoimmunity: thymoma, thymectomy, and systemic lupus erythematosus. 61
32277368 2020
5
Mixed adenoneuroendocrine carcinoma of the gallbladder, amphicrine type: Case report and review of literature. 61
32534704 2020
6
Low-Grade Myofibroblastic Sarcoma Demonstrated on 99mTc-MDP Bone Scan and 18F-FDG PET/CT. 61
32433178 2020
7
Comprehensive Characterization of the Mutational Landscape in Localized Anal Squamous Cell Carcinoma. 61
32422573 2020
8
Primary skull base neuroendocrine carcinoma-a case report and review of literature. 61
32461779 2020
9
Leiomyosarcoma of renal vein: A case report. 61
32322515 2020
10
Hemoptysis as the first symptom in the diagnosis of metastatic choriocarcinoma in the third trimester of pregnancy: A case report. 61
32426244 2020
11
Benign testicular cavernous hemangioma presenting with acute onset: A case report. 61
32454970 2020
12
Development and internal validation of a diagnostic score for gastric linitis plastica. 61
32103376 2020
13
A nomogram for predicting overall survival in patients with low-grade endometrial stromal sarcoma: A population-based analysis. 61
32558385 2020
14
The unique burden of rare cancer caregiving: caregivers of patients with Erdheim-Chester disease. 61
32090658 2020
15
Epstein-Barr Virus positive inflammatory follicular dendritic cell sarcoma presenting as solitary colonic mass: two rare cases and literature review. 61
32506505 2020
16
Hepatic adrenal adenoma-rare tumor on right lobe of liver: a case report and literature review. 61
32522174 2020
17
Gastric pyloric gland adenoma resembling a submucosal tumor: A case report. 61
32548171 2020
18
Pituicytoma associated with Cushing's disease: a case report and literature review. 61
32577204 2020
19
Hepatic Epithelioid Hemangioendothelioma as a Rare Indication for Liver Transplantation. 61
32241636 2020
20
Male adnexal tumor of probable Wolffian origin: a new entity in males similar to female adnexal tumor of probable Wolffian origin. 61
32506155 2020
21
Sex differences in solid pseudopapillary neoplasm of the pancreas: A population-based study. 61
32578384 2020
22
Rare Tumor-Normal Matched Whole Exome Sequencing Identifies Novel Genomic Pathogenic Germline and Somatic Aberrations. 61
32570879 2020
23
Molecular Characterization of Upper Tract Urothelial Carcinoma in the Era of Next-generation Sequencing: A Systematic Review of the Current Literature. 61
32571725 2020
24
Frequent traces of EBV infection in Hodgkin and non-Hodgkin lymphomas classified as EBV-negative by routine methods: expanding the landscape of EBV-related lymphomas. 61
32483241 2020
25
Tall cell carcinoma of the breast with reversed polarity (TCCRP) with mutations in the IDH2 and PIK3CA genes: a case report. 61
32474846 2020
26
The clinical treatment and outcome of cerebellopontine angle medulloblastoma: a retrospective study of 15 cases. 61
32555264 2020
27
Potential Onco-Suppressive Role of miR122 and miR144 in Uveal Melanoma through ADAM10 and C-Met Inhibition. 61
32512881 2020
28
Myointimoma of the penis. 61
32488208 2020
29
An epidemiology report for primary central nervous system tumors in adolescents and young adults: a nationwide population-based study in France, 2008-2013. 61
31796950 2020
30
Complete Response to Dual Immunotherapy in a Young Adult with Metastatic Alveolar Soft Part Sarcoma Enabled by a Drug Recovery Program in a Community Practice. 61
31855495 2020
31
Lung cancer from a focal bulla into thin-walled adenocarcinoma with ground glass opacity - an observation for more than 10 years: A case report. 61
32548161 2020
32
Primary hepatic carcinoma with inhibin positivity in a young male patient: a rare tumor previously only reported in females-case report and review of literature. 61
32533342 2020
33
Conjunctival Melanoma: Current Treatments and Future Options. 61
31965542 2020
34
Successful treatment of pulmonary inflammatory myofibroblastic tumor with platinum-pemetrexed: The first report of two cases. 61
32495499 2020
35
Analysis of Characteristics and Survival of Primary Cutaneous Adenoid Cystic Carcinoma of the Head and Neck. 61
32567392 2020
36
Adenoid cystic carcinoma of trachea: long-term disease control after endoscopic surgery and radiotherapy. 61
31793391 2020
37
Myxofibrosarcoma of the scalp with difficult preoperative diagnosis: A case report and review of the literature. 61
32548167 2020
38
Pancreatic metastasis of Merkel-cell carcinoma: a rare neoplasm of the pancreas. 61
32379470 2020
39
Immunohistochemical Profile and 47-Gene Next-Generation Sequencing (NGS) Solid Tumor Panel Analysis of a Series of 13 Strumal Carcinoids. 61
32124226 2020
40
Notable response to nivolumab during the treatment of SMARCA4-deficient thoracic sarcoma: a case report. 61
32363992 2020
41
A rare case of primary rectal choriocarcinoma and review of the literature. 61
31547751 2020
42
Perivascular Epithelioid Cell Tumor of the Urinary Bladder: A Systematic Review. 61
31865807 2020
43
Juvenile Granulosa Cell Tumors of the Ovary. 61
32561911 2020
44
Malignant fibrous histiocytoma of bone: A survival analysis from the National Cancer Database. 61
32133661 2020
45
[Long-term Survival Malignant Fibrous Histiocytoma of the Chest Wall by Postoperative Multidisciplinary Therapy;Report of a Case]. 61
32475976 2020
46
Alveolar soft part sarcoma of the lateral rectus muscle: Suture technique to prevent postoperative strabismus. 61
32322745 2020
47
Anaplastic thyroid carcinoma with rhabdoid phenotype: An unusual case and a comprehensive review. 61
32515545 2020
48
Cytotoxic T lymphocyte antigen-4 (CTLA-4) expression in chordoma and tumor-infiltrating lymphocytes (TILs) predicts prognosis of spinal chordoma. 61
32504188 2020
49
Genetic landscape and ligand-dependent activation of sonic hedgehog-Gli1 signaling in chordomas: a novel therapeutic target. 61
32404987 2020
50
Patients With Acinar Cell Carcinoma of the Pancreas After 2005: A Large Population Study. 61
32541633 2020
Sources

Variations for Rare Tumor

About this section
Sources

Expression for Rare Tumor

About this section
Search GEO for disease gene expression data for Rare Tumor.
Sources

Pathways for Rare Tumor

About this section

Pathways related to Rare Tumor according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Cytokine Signaling in Immune system 65
Show member pathways
 12.74 RET MMP2 KIT HLA-DRB1 FSCN1 FCER2
2
Cytoskeletal Signaling 4
11.75 NF2 FSCN1 DES ACTC1
3
Interleukin-4 and 13 signaling 65
11.49 MMP2 FSCN1 FCER2
4
Hematopoietic cell lineage 36
10.92 KIT HLA-DRB1 FCER2 CR2
5
Hippo signaling pathway - multiple species 36
10.78 NF2 LATS2
Sources

GO Terms for Rare Tumor

About this section

Cellular components related to Rare Tumor according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 lamellipodium GO:0030027 9.13 NF2 FSCN1 ACTC1
2 filopodium GO:0030175 8.8 NF2 FSCN1 ACTC1

Biological processes related to Rare Tumor according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 positive regulation of MAPK cascade GO:0043410 9.33 RET KIT HLA-DRB1
2 cytokine-mediated signaling pathway GO:0019221 9.26 MMP2 KIT FSCN1 FCER2
3 positive regulation of kinase activity GO:0033674 8.8 RET KIT HLA-DRB1
Sources

Sources for Rare Tumor

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....